10-K Filing

APPLIED BIOSCIENCES CORP. CIK: 1607549 FY 2017

Filing Information

Form Type	10-K
Accession Number	`0001477932-18-003243`
Period End Date	20180331
Filing Date	20180628
Fiscal Year	2017
Fiscal Period	FY
XBRL Instance	appb-20180331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 66 Income Statement 32 Cash Flow Statement 59 Stockholders Equity 20

Balance Sheet 66 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Cash	`Cash`	$212.64K	USD	Point-in-time
Cash	`Cash`	-	USD	Point-in-time
Cash	`Cash`	$60.93K	USD	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$5.68K	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$12.39K	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Inventory	`InventoryNet`	$29.07K	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventory	`InventoryNet`	$22.70K	USD	Point-in-time
Prepaids and other current assets	`OtherPrepaidExpenseCurrent`	$124.45K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Prepaids and other current assets	`OtherPrepaidExpenseCurrent`	$16.92K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$226.85K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$257.93K	USD	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$4.44K	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	10.50M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Common stock, issued	`CommonStockSharesIssued`	15.25M	shares	Point-in-time
Equity investments	`EquityMethodInvestments`	$300.00K	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	10.50M	shares	Point-in-time
Equity investments	`EquityMethodInvestments`	$468.54K	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	15.25M	shares	Point-in-time
Common stock shares to be issued	`CommonStockSharesToBeIssued`	150,000.00	shares	Point-in-time
Common stock shares to be issued	`CommonStockSharesToBeIssued`	200,000.00	shares	Point-in-time
Intangible asset, net	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Intangible asset, net	`IntangibleAssetsNetExcludingGoodwill`	$1.12M	USD	Point-in-time
Other asset	`OtherAssetsNoncurrent`	$5.50K	USD	Point-in-time
Other asset	`OtherAssetsNoncurrent`	-	USD	Point-in-time
TOTAL ASSETS	`Assets`	$1.68M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$705.33K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$21.85K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$12.30K	USD	Point-in-time
Accrued expenses	`OtherAccountsPayableAndAccruedLiabilities`	$19.29K	USD	Point-in-time
Accrued expenses	`OtherAccountsPayableAndAccruedLiabilities`	$14.04K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$31.58K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$35.88K	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at March 31, 2018 and 2017	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at March 31, 2018 and 2017	`PreferredStockValue`	-	USD	Point-in-time
Common stock; $0.00001 par value; 200,000,000 shares authorized; 10,499,610 and 15,247,600 issued and outstanding at March 31, 2018 and 2017, respectively	`CommonStockValue`	$152.00	USD	Point-in-time
Common stock; $0.00001 par value; 200,000,000 shares authorized; 10,499,610 and 15,247,600 issued and outstanding at March 31, 2018 and 2017, respectively	`CommonStockValue`	$105.00	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$1.74M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$3.05M	USD	Point-in-time
Common stock to be issued, 200,000 and 150,000 shares at March 31, 2018 and 2017, respectively	`CommonStockToBeIssued`	$526.00K	USD	Point-in-time
Common stock to be issued, 200,000 and 150,000 shares at March 31, 2018 and 2017, respectively	`CommonStockToBeIssued`	$426.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-525.83K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-2.90M	USD	Point-in-time
Total Applied BioSciences Corp. Stockholders' Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$678.47K	USD	Point-in-time
Total Applied BioSciences Corp. Stockholders' Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.64M	USD	Point-in-time
Non-controlling (deficit) interest	`MinorityInterest`	$-9.03K	USD	Point-in-time
Non-controlling (deficit) interest	`MinorityInterest`	$1.74K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$669.44K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$-8.18K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$1.64M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$705.33K	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$1.68M	USD	Point-in-time

Income Statement 32 line items

Line Item	Tag	Value	Unit	Period
Products, net	`SalesRevenueGoodsNet`	$18.05K	USD	Annual
Products, net	`SalesRevenueGoodsNet`	$197.55K	USD	Annual
Services	`SalesRevenueServicesNet`	$27.50K	USD	Annual
Services	`SalesRevenueServicesNet`	-	USD	Annual
Total Revenue	`Revenues`	$45.55K	USD	Annual
Total Revenue	`Revenues`	$197.55K	USD	Annual
COST OF REVENUE, PRODUCT	`CostOfRevenue`	$6.39K	USD	Annual
COST OF REVENUE, PRODUCT	`CostOfRevenue`	$155.55K	USD	Annual
GROSS MARGIN	`GrossProfit`	$42.01K	USD	Annual
GROSS MARGIN	`GrossProfit`	$39.16K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$356.95K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$16.90K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$141.86K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$953.48K	USD	Annual
Reverse merger costs	`NoncashMergerRelatedCosts`	-	USD	Annual
Reverse merger costs	`NoncashMergerRelatedCosts`	$376.37K	USD	Annual
Depreciation and Amortization	`DepreciationAndAmortization`	$19.96K	USD	Annual
Depreciation and Amortization	`DepreciationAndAmortization`	$224.77K	USD	Annual
Impairment of asset	`AssetImpairmentCharges`	$893.67K	USD	Annual
Impairment of asset	`AssetImpairmentCharges`	-	USD	Annual
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$2.43M	USD	Annual
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$555.08K	USD	Annual
NET LOSS	`NetIncomeLoss`	$-2.39M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-515.92K	USD	Annual
Less: Net loss attributable to non controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-10.76K	USD	Annual
Less: Net loss attributable to non controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$1.74K	USD	Annual
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	`ProfitLoss`	$-2.38M	USD	Annual
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	`ProfitLoss`	$-517.66K	USD	Annual
LOSS PER COMMON SHARE	`EarningsPerShareBasicAndDiluted`	$-0.16	USD	Annual
LOSS PER COMMON SHARE	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	15.07M	shares	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	12.05M	shares	Annual

Cash Flow Statement 59 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.39M	USD	Annual
Net loss	`NetIncomeLoss`	$-515.92K	USD	Annual
Costs of reverse merger	`NoncashMergerRelatedCosts`	-	USD	Annual
Costs of reverse merger	`NoncashMergerRelatedCosts`	$376.37K	USD	Annual
Fair value of shares issued to consultants	`FairValueOfSharesIssuedToConsultants`	$232.78K	USD	Annual
Fair value of shares issued to consultants	`FairValueOfSharesIssuedToConsultants`	-	USD	Annual
Fair value of shares issued to the Company's Chief Executive Officer	`FairValueOfSharesIssuedToCompanysChiefExecutiveOfficer`	$375.00K	USD	Annual
Depreciation	`Depreciation`	$258.00	USD	Annual
Depreciation	`Depreciation`	-	USD	Annual
Amortization of intangible	`AmortizationOfIntangibleAssets`	$19.96K	USD	Annual
Amortization of intangible	`AmortizationOfIntangibleAssets`	$224.51K	USD	Annual
Impairment of asset	`AssetImpairmentCharges`	$893.67K	USD	Annual
Impairment of asset	`AssetImpairmentCharges`	-	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-6.71K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-5.68K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-6.38K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-16.83K	USD	Annual
Prepaid and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.47K	USD	Annual
Prepaid and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-16.92K	USD	Annual
Other asset	`IncreaseDecreaseInOtherCurrentAssets`	$-5.50K	USD	Annual
Other asset	`IncreaseDecreaseInOtherCurrentAssets`	-	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$21.57K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$4.30K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-137.46K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-673.47K	USD	Annual
Acquisition of equity investment	`PaymentsToAcquireInvestments`	$300.00K	USD	Annual
Acquisition of equity investment	`PaymentsToAcquireInvestments`	$168.54K	USD	Annual
Acquisition of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Acquisition of intangible asset	`PaymentsToAcquireIntangibleAssets`	$150.00K	USD	Annual
Purchase of property and equipment	`PaymentsForProceedsFromProductiveAssets`	$4.70K	USD	Annual
Purchase of property and equipment	`PaymentsForProceedsFromProductiveAssets`	-	USD	Annual
Cash used in reverse merger	`PaymentsToAcquireProjects`	$325.00K	USD	Annual
Cash used in reverse merger	`PaymentsToAcquireProjects`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-775.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-173.24K	USD	Annual
Repurchase of shares previously issued	`PaymentsForRepurchaseOfSharesPreviouslyIssued`	$100.00K	USD	Annual
Repurchase of shares previously issued	`PaymentsForRepurchaseOfSharesPreviouslyIssued`	-	USD	Annual
Issuance of common stock for cash	`ProceedsFromIssuanceOfCommonStock`	$1.13M	USD	Annual
Issuance of common stock for cash	`ProceedsFromIssuanceOfCommonStock`	$795.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.13M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$695.00K	USD	Annual
NET CHANGE IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-151.70K	USD	Annual
NET CHANGE IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$212.64K	USD	Annual
CASH, BEGINNING OF PERIOD	`Cash`	$212.64K	USD	Point-in-time
CASH, BEGINNING OF PERIOD	`Cash`	-	USD	Point-in-time
CASH, BEGINNING OF PERIOD	`Cash`	$60.93K	USD	Point-in-time
CASH, END OF PERIOD	`Cash`	$212.64K	USD	Point-in-time
CASH, END OF PERIOD	`Cash`	-	USD	Point-in-time
CASH, END OF PERIOD	`Cash`	$60.93K	USD	Point-in-time
Fair value of shares issued to consultants recorded as prepaid	`FairValueOfSharesIssuedToConsultantsRecordedAsPrepaid`	$109.00K	USD	Annual
Fair value of shares issued to consultants recorded as prepaid	`FairValueOfSharesIssuedToConsultantsRecordedAsPrepaid`	-	USD	Annual
Issuance of stock for intangible	`IssuanceOfStockForIntangible`	-	USD	Annual
Issuance of stock for intangible	`IssuanceOfStockForIntangible`	$988.13K	USD	Annual
Inventory acquired as part of asset purchase	`NoncashOrPartNoncashAcquisitionInventoryAcquired1`	$5.87K	USD	Annual
Inventory acquired as part of asset purchase	`NoncashOrPartNoncashAcquisitionInventoryAcquired1`	-	USD	Annual
Liabilities assumed in a reverse merger	`LiabilitiesAssumedInReverseMerger`	$51.37K	USD	Annual
Liabilities assumed in a reverse merger	`LiabilitiesAssumedInReverseMerger`	-	USD	Annual
Issuance of stock for extinguishment of due to former CEO	`IssuanceOfStockForExtinguishmentOfDueToFormerCeos`	$49.52K	USD	Annual
Issuance of stock for extinguishment of due to former CEO	`IssuanceOfStockForExtinguishmentOfDueToFormerCeos`	-	USD	Annual

Stockholders Equity 20 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Shares	`SharesIssued`	10.83M	shares	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$669.44K	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-8.18K	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$1.64M	USD	Point-in-time
Payment received from stock subscription	`PaymentReceivedFromStockSubscription`	$101.00	USD	Annual
Issuance of shares upon reverse merger, Amount	`IssuanceOfSharesUponreverseMergerAmount`	-	USD	Annual
Issuance of common stock for cash, Amount	`StockIssuedDuringPeriodValueNewIssues`	$795.00K	USD	Annual
Issuance of common stock for cash, Amount	`StockIssuedDuringPeriodValueNewIssues`	$1.12M	USD	Annual
Issuance of common stock for cancellation of amount due to former CEO, Amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$49.52K	USD	Annual
Issuance of shares for acquisition of intangible, Amount	`StockIssuedDuringPeriodValueAcquisitions`	$568.00K	USD	Annual
Common stock to be issued for acquisition of intangible	`CommonStockToBeIssuedForAcquisitionOfIntangible`	$426.00K	USD	Annual
Shares repurchased for cash and cancelled, Amount	`SharesRepurchasedForCashAndCancelledAmount`	$-100.00K	USD	Annual
Fair value of shares issued to consultants for services, Amount	`SharesIssuedToConsultantsForServicesAmount`	$341.78K	USD	Annual
Fair value of shares issued to Company's CEO, Amount	`SharesIssuedToCompanysCeoAmount`	$375.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-2.39M	USD	Annual
Net loss	`NetIncomeLoss`	$-515.92K	USD	Annual
Ending Balance, Shares	`SharesIssued`	10.83M	shares	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$669.44K	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-8.18K	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$1.64M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.